Compounds > temozolomide
Page last updated: 2024-11-04

temozolomide and Angiogenesis, Pathologic

temozolomide has been researched along with Angiogenesis, Pathologic in 57 studies

Research Excerpts

ExcerptRelevanceReference
"Thirty rats with glioma were divided into control group, temozolomide (TMZ) group (TMZ 30 mg/kg once daily for 5 day), and TMZ plus Caffeine group (TMZ 30 mg/kg once daily for 5 day and caffeine 100 mg/kg once daily for 2 weeks)."8.12Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats. ( Chen, JC; Hwang, JH, 2022)
" Therefore, we aimed to examine the Synergistic effects of Gefitinib (GFI) in combination with Temozolomide on VEGF and MMPs in glioma cell line (U87MG)."8.12Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis. ( Hossienpour, M; Karami, A; Kiani, A; Mohammadi Noori, E; Najafi, K; Rahpyma, M, 2022)
" The aim of this study was to clarify whether PET with C-methyl-L-methionine (MET-PET) would supplement MRI assessing of response after initiating BEV in glioblastoma."7.83MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma. ( Beppu, T; Kato, K; Ogasawara, K; Sasaki, M; Sasaki, T; Sato, Y; Terasaki, K; Tomabechi, M, 2016)
"A total of nine patients with malignant glioma, postoperatively presenting with a Karnofsky performance score (KPS) below 70, were treated with standalone metronomic low-dose chemotherapy with temozolomide and celecoxib (cyclo-oxygenase-2 inhibitor)."7.81Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. ( Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J, 2015)
"Our laboratory reported that Irinophore C™ (IrC™; a lipid-based nanoparticulate formulation of irinotecan) is effective against an orthotopic model of glioblastoma (GBM) and that treatment with IrC™ was associated with vascular normalization within the tumor."7.81Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma. ( Anantha, M; Backstrom, I; Bally, MB; Chu, F; Kalra, J; Masin, D; Strutt, D; Verreault, M; Walker, D; Waterhouse, D; Wehbe, M; Yapp, DT, 2015)
"Present work mainly evaluated the inhibitory effects of lidamycin (LDM), an enediyne antibiotic, on angiogenesis or glioma-induced angiogenesis in vitro and in vivo, especially its synergistic anti-angiogenesis with temozolomide (TMZ)."7.80Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin. ( Li, XQ; Li, Y; Liu, H; Ouyang, ZG; Shang, Y; Zhang, SH; Zhen, YS, 2014)
"In the U87 intracerebral glioma model, within the first day of administration of cediranib, the intratumoral concentrations of TMZ in tumor ECF were slightly, but not statistically significantly, increased when compared to the treatment of TMZ alone with radiographic evidence of a normalized BBB."7.79Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model. ( Blakeley, JO; Brem, H; Grossman, R; Khan, U; Kim, E; Pathak, AP; Rudek, MA; Tyler, B; Zadnik, P, 2013)
"Bortezomib induced caspase-3 activation and apoptotic cell death in stable glioma cell lines and in glioma stem-like cells (GSCs) derived from malignant tumor specimens Furthermore, TMZ-resistant glioma cell lines retained susceptibility to the proteasome inhibition."7.79Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. ( Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J, 2013)
" Recently, in a phase II trial in Brazil for the treatment of temozolomide (TMZ)-resistant malignant gliomas, POH was well tolerated when administered intranasally."7.78Perillyl alcohol for the treatment of temozolomide-resistant gliomas. ( Chen, TC; Cho, HY; Goldkorn, A; Hofman, FM; Jhaveri, N; Lee, DJ; Leong, MN; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Tseng, J; Wang, W; Xu, T, 2012)
"Temozolomide (TM) has anti-tumor activity in patients with malignant glioma."7.76Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Liu, JM; Tang, GS; Wang, Y; Yue, ZJ; Zhang, H; Zhang, YH, 2010)
"Temozolomide is considered the standard of care and drug of choice for the treatment of initially diagnosed malignant gliomas."7.75Glioma-associated endothelial cells are chemoresistant to temozolomide. ( Chen, TC; Golden, EB; Hofman, FM; Pen, L; Schönthal, AH; Sivakumar, W; Virrey, JJ; Wang, W, 2009)
"The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma."7.73Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS, 2006)
" Metronomic dosing of cytotoxic chemotherapy has emerged as a promising option to achieve this objective."6.82Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. ( Alsop, DC; Callahan, A; Giarusso, B; O'Loughlin, L; Timmons, J; Wong, ET, 2016)
" Thus, our results show that polymeric nanocapsules are able to increase the intratumoral bioavailability of indomethacin and reduce the growth of implanted gliomas."5.35Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. ( Battastini, AM; Bernardi, A; Braganhol, E; Edelweiss, MI; Figueiró, F; Guterres, SS; Jäger, E; Pohlmann, AR, 2009)
"Thirteen patients with recurrent glioblastoma were enrolled in RTOG 0625/ACRIN 6677, a prospective multicenter trial in which bevacizumab was used in combination with either temozolomide or irinotecan."5.17Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. ( Barboriak, DP; Bokstein, F; Boxerman, JL; Gilbert, MR; McKinstry, RC; Ratai, EM; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z, 2013)
"A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)."5.12Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007)
"In the last decade, phase III trials on novel compounds largely failed to introduce efficacious pharmacotherapies beyond temozolomide in glioblastoma."4.93Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives. ( Gramatzki, D; Roth, P; Seystahl, K; Weller, M, 2016)
"Thirty rats with glioma were divided into control group, temozolomide (TMZ) group (TMZ 30 mg/kg once daily for 5 day), and TMZ plus Caffeine group (TMZ 30 mg/kg once daily for 5 day and caffeine 100 mg/kg once daily for 2 weeks)."4.12Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats. ( Chen, JC; Hwang, JH, 2022)
" Therefore, we aimed to examine the Synergistic effects of Gefitinib (GFI) in combination with Temozolomide on VEGF and MMPs in glioma cell line (U87MG)."4.12Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis. ( Hossienpour, M; Karami, A; Kiani, A; Mohammadi Noori, E; Najafi, K; Rahpyma, M, 2022)
" The aim of this study was to clarify whether PET with C-methyl-L-methionine (MET-PET) would supplement MRI assessing of response after initiating BEV in glioblastoma."3.83MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma. ( Beppu, T; Kato, K; Ogasawara, K; Sasaki, M; Sasaki, T; Sato, Y; Terasaki, K; Tomabechi, M, 2016)
"Our laboratory reported that Irinophore C™ (IrC™; a lipid-based nanoparticulate formulation of irinotecan) is effective against an orthotopic model of glioblastoma (GBM) and that treatment with IrC™ was associated with vascular normalization within the tumor."3.81Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma. ( Anantha, M; Backstrom, I; Bally, MB; Chu, F; Kalra, J; Masin, D; Strutt, D; Verreault, M; Walker, D; Waterhouse, D; Wehbe, M; Yapp, DT, 2015)
"A total of nine patients with malignant glioma, postoperatively presenting with a Karnofsky performance score (KPS) below 70, were treated with standalone metronomic low-dose chemotherapy with temozolomide and celecoxib (cyclo-oxygenase-2 inhibitor)."3.81Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. ( Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J, 2015)
"Present work mainly evaluated the inhibitory effects of lidamycin (LDM), an enediyne antibiotic, on angiogenesis or glioma-induced angiogenesis in vitro and in vivo, especially its synergistic anti-angiogenesis with temozolomide (TMZ)."3.80Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin. ( Li, XQ; Li, Y; Liu, H; Ouyang, ZG; Shang, Y; Zhang, SH; Zhen, YS, 2014)
"Bortezomib induced caspase-3 activation and apoptotic cell death in stable glioma cell lines and in glioma stem-like cells (GSCs) derived from malignant tumor specimens Furthermore, TMZ-resistant glioma cell lines retained susceptibility to the proteasome inhibition."3.79Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. ( Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J, 2013)
"In the U87 intracerebral glioma model, within the first day of administration of cediranib, the intratumoral concentrations of TMZ in tumor ECF were slightly, but not statistically significantly, increased when compared to the treatment of TMZ alone with radiographic evidence of a normalized BBB."3.79Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model. ( Blakeley, JO; Brem, H; Grossman, R; Khan, U; Kim, E; Pathak, AP; Rudek, MA; Tyler, B; Zadnik, P, 2013)
" Recently, in a phase II trial in Brazil for the treatment of temozolomide (TMZ)-resistant malignant gliomas, POH was well tolerated when administered intranasally."3.78Perillyl alcohol for the treatment of temozolomide-resistant gliomas. ( Chen, TC; Cho, HY; Goldkorn, A; Hofman, FM; Jhaveri, N; Lee, DJ; Leong, MN; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Tseng, J; Wang, W; Xu, T, 2012)
"Temozolomide (TM) has anti-tumor activity in patients with malignant glioma."3.76Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Liu, JM; Tang, GS; Wang, Y; Yue, ZJ; Zhang, H; Zhang, YH, 2010)
"Temozolomide is considered the standard of care and drug of choice for the treatment of initially diagnosed malignant gliomas."3.75Glioma-associated endothelial cells are chemoresistant to temozolomide. ( Chen, TC; Golden, EB; Hofman, FM; Pen, L; Schönthal, AH; Sivakumar, W; Virrey, JJ; Wang, W, 2009)
"In mice bearing SF188V+ human glioma xenografts, measurements of temozolomide pharmacokinetic properties and sunitinib pharmacodynamic activities were evaluated, the latter including determinants for vascular normalization, including CD31, collagen IV, and alpha-SMA."3.74Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. ( Gallo, JM; Guo, P; Zhou, Q, 2008)
"The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma."3.73Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS, 2006)
" Metronomic dosing of cytotoxic chemotherapy has emerged as a promising option to achieve this objective."2.82Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. ( Alsop, DC; Callahan, A; Giarusso, B; O'Loughlin, L; Timmons, J; Wong, ET, 2016)
"Glioblastomas are rich in blood vessels (i."2.58Anti-angiogenic therapy for high-grade glioma. ( Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H, 2018)
"Aggressive pituitary adenomas, defined from a clinical perspective, have earlier and more frequent recurrences and can be resistant to conventional treatments."2.50Aggressive pituitary adenomas--diagnosis and emerging treatments. ( Cusimano, MD; Di Ieva, A; Kovacs, K; Rotondo, F; Syro, LV, 2014)
"Primary brain tumors are hallmarked for their destructive activity on the microenvironment and vasculature."1.43A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain. ( Buchfelder, M; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Hock, S; Savaskan, NE; Sehm, T; Yakubov, E, 2016)
"Glioma is one of the most aggressive and lethal human brain tumors."1.40MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. ( Chen, Q; Jiang, BH; Jiang, C; Jiang, T; Kang, C; Li, C; Li, H; Liu, LZ; Liu, N; Liu, X; Qian, X; Shi, Z; Wang, L; Wang, X; You, Y, 2014)
"To report the serial development of oral mucositis following infusion of bevacizumab in a young woman with a malignant brain tumor and history of cutaneous psoriasis."1.38Bevacizumab-induced oral mucositis in background of cutaneous plaque-type psoriasis. ( Cuellar, S; Popa, AM; Radhakrishnan, L; Valla, K; Villano, JL, 2012)
" These combinations appear to be the most promising for in vivo pre-clinical studies, with a view to testing in melanoma patients as a continuous dosing strategy, due to the in vitro additive inhibitory effect on growth seen in both endothelial and cancer cells."1.36Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy. ( Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P, 2010)
" Thus, our results show that polymeric nanocapsules are able to increase the intratumoral bioavailability of indomethacin and reduce the growth of implanted gliomas."1.35Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. ( Battastini, AM; Bernardi, A; Braganhol, E; Edelweiss, MI; Figueiró, F; Guterres, SS; Jäger, E; Pohlmann, AR, 2009)
"Gliomatosis cerebri is a rare primary cerebral tumour entity characterized by diffuse infiltrative growth patterns representing a WHO grade III malignancy."1.35First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity. ( Brockmann, MA; Hermes, P; Kohlhof, P; Neumaier-Probst, E; Schmieder, K; Seiz, M; Tuettenberg, J; Vajkoczy, P; VON Deimling, A, 2009)
"Glioblastomas are highly aggressive primary brain tumors."1.35Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. ( Claes, A; Heerschap, A; Jeuken, J; Leenders, WP; Maass, C; Wesseling, P, 2008)
"Temozolomide is a proautophagic (type II programmed cell death) drug and can thus circumvent part of the glioblastoma resistance to apoptosis."1.35[The sodium pump could constitute a new target to combat glioblastomas]. ( Kiss, R; Lefranc, F; Mijatovic, T, 2008)

Research

Studies (57)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (7.02)18.2507
2000's14 (24.56)29.6817
2010's33 (57.89)24.3611
2020's6 (10.53)2.80

Authors

AuthorsStudies
Urbantat, RM1
Jelgersma, C1
Brandenburg, S1
Nieminen-Kelhä, M1
Kremenetskaia, I1
Zollfrank, J1
Mueller, S1
Rubarth, K1
Koch, A1
Vajkoczy, P3
Acker, G1
Pai, FC1
Huang, HW1
Tsai, YL1
Tsai, WC1
Cheng, YC1
Chang, HH1
Chen, Y4
Fu, X1
Xiong, B1
Zhao, M1
Wan, W1
Zhang, S3
Wu, X2
Xu, J1
Bittencourt, LFF1
Negreiros-Lima, GL1
Sousa, LP1
Silva, AG1
Souza, IBS1
Ribeiro, RIMA1
Dutra, MF1
Silva, RF1
Dias, ACF1
Soriani, FM1
Martins, WK1
Barcelos, LS1
Çetin, A1
Biltekin, B1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H5
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X10
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D3
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y2
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J4
Zhang, E1
Zhang, J3
Li, Y6
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Wang, Y3
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X2
Ren, Y1
Li, J8
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X2
Wang, W3
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L2
Zhu, J2
Zhang, L3
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Wang, X6
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y4
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Yang, X3
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS3
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Zhang, H2
Yang, T2
Dong, Y1
Xu, Y2
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Wang, H2
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Zhang, X4
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C3
Chen, W2
Hu, X1
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y2
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q2
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H3
He, Z1
Chen, B1
Wu, J1
Du, X2
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X2
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P2
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H2
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H2
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Chen, JC1
Hwang, JH1
Karami, A1
Hossienpour, M1
Mohammadi Noori, E1
Rahpyma, M1
Najafi, K1
Kiani, A1
Mathivet, T1
Bouleti, C1
Van Woensel, M1
Stanchi, F1
Verschuere, T1
Phng, LK1
Dejaegher, J1
Balcer, M1
Matsumoto, K1
Georgieva, PB1
Belmans, J1
Sciot, R1
Stockmann, C1
Mazzone, M1
De Vleeschouwer, S1
Gerhardt, H1
Xue, W1
Wu, H1
Xie, T1
Tong, H1
Guo, Y1
Zhang, W1
Tong, L1
Yi, L1
Liu, P1
Abeysekera, IR1
Hai, L1
Li, T1
Tao, Z1
Xie, Y1
Yu, S1
Yuan, F1
Calastri, MCJ1
Rodrigues, NLTO1
Hatori, G1
Gregório, ML1
Brancati, CIFO1
Zanovelo, EM1
Ferraz Filho, JRL1
Neiva, CM1
Rodrigues Junior, ACP1
Godoy, MF1
Lancelloti, CLP1
Tognola, WA1
Souza, DRS1
Eisemann, T1
Costa, B1
Harter, PN1
Wick, W2
Mittelbronn, M1
Angel, P1
Peterziel, H1
Ameratunga, M1
Pavlakis, N2
Wheeler, H2
Grant, R2
Simes, J1
Khasraw, M2
Ratai, EM1
Zhang, Z2
Snyder, BS1
Boxerman, JL1
Safriel, Y1
McKinstry, RC1
Bokstein, F1
Gilbert, MR1
Sorensen, AG1
Barboriak, DP1
Grossman, R1
Tyler, B1
Rudek, MA1
Kim, E1
Zadnik, P1
Khan, U1
Blakeley, JO1
Pathak, AP1
Brem, H1
Stacchiotti, S1
Tortoreto, M1
Bozzi, F1
Tamborini, E1
Morosi, C1
Messina, A1
Libertini, M1
Palassini, E1
Cominetti, D1
Negri, T1
Gronchi, A1
Pilotti, S1
Zaffaroni, N1
Casali, PG1
Bota, DA1
Alexandru, D1
Keir, ST1
Bigner, D1
Vredenburgh, J1
Friedman, HS1
Li, XQ1
Ouyang, ZG1
Zhang, SH1
Shang, Y1
Zhen, YS1
Di Ieva, A1
Rotondo, F1
Syro, LV1
Cusimano, MD1
Kovacs, K1
Shi, Z1
Qian, X1
Jiang, C1
Kang, C1
Jiang, T1
Liu, LZ1
You, Y1
Liu, N1
Jiang, BH1
Ameratunga, MS1
Kessler, T1
Sahm, F1
Blaes, J1
Osswald, M1
Rübmann, P1
Milford, D1
Urban, S1
Jestaedt, L1
Heiland, S1
Bendszus, M1
Hertenstein, A1
Pfenning, PN1
Ruiz de Almodóvar, C1
Wick, A1
Winkler, F1
von Deimling, A2
Platten, M1
Weiler, M1
Tabouret, E1
Tchoghandjian, A1
Denicolai, E1
Delfino, C1
Metellus, P1
Graillon, T1
Boucard, C1
Nanni, I1
Padovani, L1
Ouafik, L1
Figarella-Branger, D1
Chinot, O1
Kerschbaumer, J1
Schmidt, FA1
Grams, AE1
Nowosielski, M1
Pinggera, D1
Brawanski, KR1
Petr, O1
Thomé, C1
Tuettenberg, J3
Seiz, M2
Freyschlag, CF1
Verreault, M1
Wehbe, M1
Strutt, D1
Masin, D1
Anantha, M1
Walker, D1
Chu, F1
Backstrom, I1
Kalra, J1
Waterhouse, D1
Yapp, DT1
Bally, MB1
Ghoochani, A1
Yakubov, E1
Sehm, T1
Fan, Z1
Hock, S1
Buchfelder, M1
Eyüpoglu, IY1
Savaskan, NE1
Huang, M1
Liu, T1
Ma, P1
Mitteer, RA1
Kim, HJ1
Yeo, E1
Cai, P1
Zhao, B1
Roccograndi, L1
O'Rourke, DM1
Dahmane, N1
Gong, Y1
Koumenis, C1
Seystahl, K1
Gramatzki, D1
Roth, P1
Weller, M1
Beppu, T1
Terasaki, K1
Sasaki, T1
Sato, Y1
Tomabechi, M1
Kato, K1
Sasaki, M1
Ogasawara, K1
Wong, ET2
Timmons, J1
Callahan, A1
O'Loughlin, L1
Giarusso, B1
Alsop, DC1
Mathieu, V2
De Nève, N1
Le Mercier, M2
Dewelle, J1
Gaussin, JF1
Dehoux, M1
Kiss, R3
Lefranc, F3
Bernardi, A1
Braganhol, E1
Jäger, E1
Figueiró, F1
Edelweiss, MI1
Pohlmann, AR1
Guterres, SS1
Battastini, AM1
Laigle-Donadey, F1
Dehais, C1
Mazeron, JJ1
Sanson, M1
Virrey, JJ1
Golden, EB1
Sivakumar, W1
Pen, L1
Schönthal, AH2
Hofman, FM2
Chen, TC2
Kohlhof, P1
Brockmann, MA1
Neumaier-Probst, E1
Hermes, P1
Schmieder, K1
Chahal, M1
Lesniak, D1
Graham, K1
Famulski, K1
Christensen, JG1
Aghi, M1
Jacques, A1
Murray, D1
Sabri, S1
Abdulkarim, B1
Murray, A1
Little, SJ1
Stanley, P1
Maraveyas, A1
Cawkwell, L1
Zhang, YH1
Yue, ZJ1
Tang, GS1
Liu, JM1
Brem, S1
Wolf, A1
Agnihotri, S1
Micallef, J1
Mukherjee, J1
Sabha, N1
Cairns, R1
Hawkins, C1
Guha, A1
Cho, HY1
Jhaveri, N1
Torres, S1
Tseng, J1
Leong, MN1
Lee, DJ1
Goldkorn, A1
Xu, T1
Petasis, NA1
Louie, SG1
Demirci, U1
Yaman, M1
Buyukberber, S1
Coskun, U1
Baykara, M1
Uslu, K1
Ozet, A1
Benekli, M1
Bagriacik, EU1
Popa, AM1
Valla, K1
Radhakrishnan, L1
Cuellar, S1
Villano, JL1
Amiri, KI1
Horton, LW1
LaFleur, BJ1
Sosman, JA1
Richmond, A1
Grobholz, R1
Korn, T1
Wenz, F1
Erber, R1
Son, MJ2
Kim, JS2
Kim, MH2
Song, HS2
Kim, JT2
Shin, T1
Jeon, HJ1
Park, SY1
Kim, YJ1
Kim, JH1
Nam, DH2
Ko, KW1
Kong, DS1
Kang, CM1
Shin, HJ1
Eoh, W1
Claes, A1
Jeuken, J1
Maass, C1
Heerschap, A1
Leenders, WP1
Zhou, Q1
Guo, P1
Gallo, JM3
Hau, P1
Kunz-Schughart, L1
Bogdahn, U1
Baumgart, U1
Hirschmann, B1
Weimann, E1
Muhleisen, H1
Ruemmele, P1
Steinbrecher, A1
Reichle, A1
Mijatovic, T2
Haibe-Kains, B1
Bontempi, G1
Decaestecker, C1
Devineni, D1
Klein-Szanto, A2
Weiss, GR1
Burris, HA1
Eckhardt, SG1
Rodriguez, GI1
Sharma, S1
Valley, A1
Ma, J1
Fei, ZL1
Burton, E1
Prados, M1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients[NCT03023124]Phase 250 participants (Anticipated)Interventional2018-03-04Recruiting
Evaluation of Topical Application of 5% Imiquimod, 0.05% Imiquimod and 0.05% Nanoencapsulated Imiquimod Gel in the Treatment of Actinic Cheilitis: a Randomized Controlled Trial[NCT04219358]Phase 149 participants (Actual)Interventional2019-03-23Terminated (stopped due to Study terminated because of COVID19 pandemics.)
A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients With an Unmethylated MGMT Gene Promoter[NCT02928575]Phase 245 participants (Anticipated)Interventional2012-08-31Recruiting
Metabolomic Profiling of Erector Spinae Plane Block for Breast Cancer Surgery[NCT04689945]91 participants (Actual)Observational2021-02-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

8 reviews available for temozolomide and Angiogenesis, Pathologic

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Anti-angiogenic therapy for high-grade glioma.
    The Cochrane database of systematic reviews, 2018, 11-22, Volume: 11

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai

2018
Aggressive pituitary adenomas--diagnosis and emerging treatments.
    Nature reviews. Endocrinology, 2014, Volume: 10, Issue:7

    Topics: Adenoma; Biomarkers, Tumor; Dacarbazine; Humans; Ki-67 Antigen; Neoplasm Invasiveness; Neovasculariz

2014
Antiangiogenic therapy for high-grade glioma.
    The Cochrane database of systematic reviews, 2014, Sep-22, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai

2014
Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:9

    Topics: Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Neovascu

2016
[Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
    Bulletin du cancer, 2009, Volume: 96, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2009
New anticancer agents.
    Cancer chemotherapy and biological response modifiers, 1997, Volume: 17

    Topics: Animals; Antineoplastic Agents; Dacarbazine; Humans; Lactones; Macrolides; Neovascularization, Patho

1997
New chemotherapy options for the treatment of malignant gliomas.
    Current opinion in oncology, 1999, Volume: 11, Issue:3

    Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine;

1999

Trials

4 trials available for temozolomide and Angiogenesis, Pathologic

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
    Neuro-oncology, 2013, Volume: 15, Issue:7

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Be

2013
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.
    BMC cancer, 2016, 11-22, Volume: 16, Issue:1

    Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bioma

2016
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
    Oncology, 2007, Volume: 73, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin

2007

Other Studies

46 other studies available for temozolomide and Angiogenesis, Pathologic

ArticleYear
Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.
    International journal of molecular sciences, 2021, Oct-16, Volume: 22, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined

2021
Inhibition of FABP6 Reduces Tumor Cell Invasion and Angiogenesis through the Decrease in MMP-2 and VEGF in Human Glioblastoma Cells.
    Cells, 2021, 10-17, Volume: 10, Issue:10

    Topics: Animals; Cell Line, Tumor; Cell Movement; Clone Cells; Disease Progression; Extracellular Matrix; Fa

2021
Quinacrine is active in preclinical models of glioblastoma through suppressing angiogenesis, inducing oxidative stress and activating AMPK.
    Toxicology in vitro : an international journal published in association with BIBRA, 2022, Volume: 83

    Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Glioblastom

2022
G3BP1 knockdown sensitizes U87 glioblastoma cell line to Bortezomib by inhibiting stress granules assembly and potentializing apoptosis.
    Journal of neuro-oncology, 2019, Volume: 144, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Bortezomib; Cell Proliferation;

2019
Combining Ellagic Acid with Temozolomide Mediates the Cadherin Switch and Angiogenesis in a Glioblastoma Model.
    World neurosurgery, 2019, Volume: 132

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Line, Tumor; Disease Models

2019
Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats.
    Nutrition and cancer, 2022, Volume: 74, Issue:3

    Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Caffeine; Cell Line, Tumor; Endoplasmic Reticulum St

2022
Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis.
    Nutrition and cancer, 2022, Volume: 74, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Dru

2022
Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.
    EMBO molecular medicine, 2017, Volume: 9, Issue:12

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood Vessels; Brain Neoplasms;

2017
Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment.
    Scientific reports, 2017, 10-24, Volume: 7, Issue:1

    Topics: Animals; Bevacizumab; Cell Line, Tumor; Cell Transformation, Neoplastic; Contrast Media; Drug Resist

2017
Tumour cell dormancy as a contributor to the reduced survival of GBM patients who received standard therapy.
    Oncology reports, 2018, Volume: 40, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Cell Movement; Cell Proliferation; Combi

2018
Genetic variants related to angiogenesis and apoptosis in patients with glioma.
    Arquivos de neuro-psiquiatria, 2018, Volume: 76, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neop

2018
Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.
    Neuro-oncology, 2019, 02-19, Volume: 21, Issue:3

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cel

2019
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop

2013
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Sep-15, Volume: 19, Issue:18

    Topics: Adult; Aged; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2013
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Journal of neurosurgery, 2013, Volume: 119, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosi

2013
Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
    Cancer biology & therapy, 2014, Volume: 15, Issue:4

    Topics: Aminoglycosides; Angiogenesis Inhibitors; Animals; Anti-Bacterial Agents; Apoptosis; Brain; Brain Ne

2014
MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.
    Neuro-oncology, 2014, Volume: 16, Issue:10

    Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Genes

2014
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Oncotarget, 2015, Oct-13, Volume: 6, Issue:31

    Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cel

2015
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
    Oncotarget, 2015, May-10, Volume: 6, Issue:13

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Benzylamines; Brain Neoplasms; Chemokine

2015
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment.
    Anticancer research, 2015, Volume: 35, Issue:9

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Che

2015
Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
    Journal of controlled release : official journal of the Controlled Release Society, 2015, Dec-28, Volume: 220, Issue:Pt A

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth

2015
A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain.
    Oncotarget, 2016, Jan-12, Volume: 7, Issue:2

    Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D

2016
c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma.
    The Journal of clinical investigation, 2016, 05-02, Volume: 126, Issue:5

    Topics: Animals; Cell Hypoxia; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; En

2016
MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma.
    Clinical nuclear medicine, 2016, Volume: 41, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi

2016
Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
    Neoplasia (New York, N.Y.), 2008, Volume: 10, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo

2008
Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model.
    Cancer letters, 2009, Aug-18, Volume: 281, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Body Weight; Cell Division; Cell

2009
Glioma-associated endothelial cells are chemoresistant to temozolomide.
    Journal of neuro-oncology, 2009, Volume: 95, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Movement; Cell Prolife

2009
First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity.
    Anticancer research, 2009, Volume: 29, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Proliferation; Cyclooxy

2009
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
    Neuro-oncology, 2010, Volume: 12, Issue:8

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western;

2010
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
    Oncology reports, 2010, Volume: 24, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Lin

2010
Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2010, Volume: 76, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc

2010
Taming glioblastoma by targeting angiogenesis: 3 years later.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-10, Volume: 29, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2011
Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme.
    The Journal of experimental medicine, 2011, Feb-14, Volume: 208, Issue:2

    Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Primers; Flow Cytometry; F

2011
Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:11

    Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferati

2012
Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy.
    International immunopharmacology, 2012, Volume: 14, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Dac

2012
Bevacizumab-induced oral mucositis in background of cutaneous plaque-type psoriasis.
    The Annals of pharmacotherapy, 2012, Volume: 46, Issue:11

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating

2012
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
    Cancer research, 2004, Jul-15, Volume: 64, Issue:14

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2004
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.
    Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:1

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother

2005
Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
    International journal of oncology, 2006, Volume: 28, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel

2006
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
    Oncology reports, 2006, Volume: 16, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Disease Models

2006
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-B

2008
Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-01, Volume: 14, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Collagen; Co

2008
[The sodium pump could constitute a new target to combat glioblastomas].
    Bulletin du cancer, 2008, Volume: 95, Issue:3

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy;

2008
Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses.
    Journal of neuropathology and experimental neurology, 2008, Volume: 67, Issue:5

    Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Reg

2008
Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
    Cancer research, 1996, May-01, Volume: 56, Issue:9

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cyclohexan

1996
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.
    Clinical & experimental metastasis, 1998, Volume: 16, Issue:6

    Topics: Animals; Antineoplastic Agents, Alkylating; Capillaries; Carmustine; Cell Hypoxia; Dacarbazine; DNA,

1998